FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

BPI Labs Cited After FDA Inspection

[ Price : $8.95]

FDA issues BPI Labs a Form-483 following an April inspection for potential cross-contamination risks at its outsourcing facility i...

Replimune to Refile Controversial Melanoma BLA

[ Price : $8.95]

Replimune plans to resubmit its controversial BLA for RP1 (vusolimogene oderparepvec) in combination with Opdivo as a treatment fo...

DexCom Alert on Stolen Glucose Monitoring Sensors

[ Price : $8.95]

DexCom says it has identified two lots of stolen Dexcom G7 continuous glucose monitoring sensors that were diverted into the comme...

Medical Device Human Factors Info Submission Guidance

[ Price : $8.95]

FDA publishes a final guidance to assist sponsors in submitting human factors information with medical device marketing applicatio...

2 Bioequivalence Guidances Published

[ Price : $8.95]

FDA publishes two final guidances on aspects of establishing bioequivalence.

Change FDA Sepsis Screening Strategy: Dingell and McCormick

[ Price : $8.95]

Reps. Debbie Dingell and Rich McCormick say FDA should update its strategy for evaluating and identifying sepsis as a means to exc...

FDA Marks 50th Anniversary of Device Amendments

[ Price : $8.95]

FDA marks the 50th anniversary of the 1976 Medical Device Amendments by highlighting the laws lasting role in shaping the modern o...

FDA Updates Phillips Trilogy Ventilator Corrections

[ Price : $8.95]

FDA issues an update on a Philips Respironics device correction involving its Trilogy Evo platform ventilators, citing risks that ...

Berens Infantile Niemann-Pick disease Drug Review Extended

[ Price : $8.95]

FDA extends by three months its review timeline of a Beren Therapeutics NDA for adrabetadex for treating infantile-onset Niemann-P...

Imfinzi Get Expanded Use in High-Risk Bladder Cancer

[ Price : $8.95]

FDA approves AstraZenecas Imfinzi (durvalumab) in combination with Bacillus Calmette-Guerin (BCG) for treating adults with BCG-nav...